#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mixed-type liposarcoma Neurodevelopmental disorder Congenital pseudarthrosis Glomerulonephritis chronic Cholangiosarcoma Oropharyngeal squamous cell carcinoma Oesophageal squamous cell carcinoma stage II Prophylaxis against transplant rejection Nephrotic syndrome Solitary fibrous tumour Congenital hypotransferrinaemia Acute on chronic liver failure Vaginal cancer Dementia Ewing's sarcoma More trials…

    Learn about Rare Diseases

    Haemophilia B with anti factor IX – Treatment Netherton’s syndrome – Basic Information Langerhans’ cell histiocytosis – Treatment Hereditary hypophosphataemic rickets – Trials in Disease Alagille syndrome – Trials in Disease Indolent systemic mastocytosis – Diagnostics Mucopolysaccharidosis I – Diagnostics Rhabdoid tumour – Trials in Disease Leiomyosarcoma – Life with Disease Bronchiolitis obliterans syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pamapimod Etifoxine Hydrochloride Mirtazapine Gs-1427 Gfh925 Ucp2 Brimonidine Fluticasone Furoate Mbf-015 Atl001 ARLOCABTAGENE AUTOLEUCEL Cenobamate Oditrasertib Felzartamab Cabotegravir GSKVX000000048111 Piperacillin Protease GSK5764227 Propofol More therapies…

    Learn about Your Condition

    Rosai-Dorfman syndrome Atopic keratoconjunctivitis Partial lipodystrophy Arteriovenous graft thrombosis Blood iron increased Muscle injury Dyspepsia Breast cancer female Staphylococcal bacteraemia Cervix carcinoma stage III Decreased appetite Cystic fibrosis lung Elderly Liposarcoma metastatic Intervertebral disc protrusion More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mental Disorders

  • Testing dehydroepiandrosterone combined with standard antidepressants for patients with treatment-resistant depression

    Recruiting

    3 1 1
    Investigated Diseases:
    • Depression
    Investigated Drugs:
    • Prasterone
    • Lactose Monohydrate
    Germany
  • A Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress

    Recruiting

    2 1 1
    Bulgaria Czechia Germany Hungary Poland Romania +1
  • A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Czechia France Hungary Italy Poland
  • Study of xanomeline tartrate and trospium chloride combination for treating agitation in Alzheimer’s disease patients

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Croatia Greece Portugal Romania Spain
  • Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Croatia Czechia Germany Greece Italy Poland +2
  • Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Finland France Germany Greece Italy The Netherlands +4
Previous Page
1 2 3 4 5 6 … 40
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!